SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cell MedX Corp. – ‘8-K’ for 11/13/14 – EX-10.4

On:  Tuesday, 11/18/14, at 11:23am ET   ·   For:  11/13/14   ·   Accession #:  1594062-14-361   ·   File #:  0-54500

Previous ‘8-K’:  ‘8-K’ on 11/3/14 for 10/28/14   ·   Next:  ‘8-K’ on 12/3/14 for 11/25/14   ·   Latest:  ‘8-K’ on 4/4/24 for 4/1/24   ·   19 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/18/14  Cell MedX Corp.                   8-K:1,9    11/13/14    2:48K                                    Ideal Connection, Inc/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 2: EX-10.4     Amendment No. 2 to Technology Purchase Agreement    HTML     18K 
                          Dated Effective as of November 13, 2014                
                          Among Cell Medx Corp., Jean Arnett, and                
                          Brad Hargreaves.                                       


EX-10.4   —   Amendment No. 2 to Technology Purchase Agreement Dated Effective as of November 13, 2014 Among Cell Medx Corp., Jean Arnett, and Brad Hargreaves.


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]






AMENDMENT NO. 2 TO TECHNOLOGY PURCHASE AGREEMENT


THIS AGREEMENT is dated effective this 13th day of November, 2014


AMONG:

JEAN ARNETT, businessperson, having an address at 121 - 3989 Henning Drive, Burnaby, BC  V5C 6N5

(hereinafter called “Arnett”)
OF THE FIRST PART
AND:

BRAD HARGREAVES, businessperson, having an address at 121 - 3989 Henning Drive, Burnaby, BC  V5C 6N5

(hereinafter called “Hargreaves”)
OF THE SECOND PART

(Arnett and Hargreaves collectively being the “Vendors”)

AND:
CELL MEDX CORP., a Nevada corporation having an address at 4575 Dean Martin Drive 2206, Las Vegas, Nevada 89103

(hereinafter called the “Company”)
OF THE THIRD PART

WHEREAS:

A. The Vendors and the Company are parties to that Technology Purchase Agreement dated effective as of the 16th day of October, 2014 and as previously amended by that Amendment No. 1 to Technology Purchase Agreement dated effective the 28th day of October, 2014 (as amended, the “Technology Purchase Agreement”); and
 
B. The Vendors and the Company wish to further amend the terms of the Technology Purchase Agreement as set forth herein,
 
NOW THEREFORE THIS AGREEMENT WITNESSES THAT for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto mutually covenant and agree as follows:

1. Unless otherwise defined in this Agreement, capitalized terms used herein and in the recitals hereto shall have the meanings set forth in the Technology Purchase Agreement.
 
2. The parties agree that the Technology Purchase Agreement shall be, and hereby is, amended as follows:
 
 
Page 1 of 2

 
(a) Section 3.1 of the Technology Purchase Agreement shall be deleted in its entirety and replaced with the following:
 
3.1  Closing.  Subject to the satisfaction or waiver of all of the conditions precedent to Closing as set out in this Agreement, Closing of the transactions contemplated herein shall take place at such place and time on the Closing Date as may be agreed to by the parties hereto.  The Closing Date shall be such date as is agreed upon by the parties hereto, but shall be no later than December 1, 2014.  Unless otherwise agreed to by each of the parties hereto, if Closing does not occur on or before December 1, 2014, this Agreement shall automatically be terminated and of no further force and effect except with respect to the provisions of Sections 5.6 and 5.8 of this Agreement.

3. Except as modified by this Agreement, the Technology Purchase Agreement remains in full force and effect in accordance with its terms, and are hereby ratified and confirmed in all respect by the Company and the Vendors.

4. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterpart have been signed by each party hereto and delivered to the other parties.

IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first written above.

CELL MEDX CORP.
   
a Nevada corporation by its authorized signatory:
 
   
     
   
   
Title: Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
   
     

     
   
   
     
     
     
     
 



 
Page 2 of 2

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
12/1/14None on these Dates
Filed on:11/18/14
For Period End:11/13/14
 List all Filings


19 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/15/24  Cell MedX Corp.                   10-Q        2/29/24   53:2.7M                                   Empire Stock Transf… Inc
 1/16/24  Cell MedX Corp.                   10-Q       11/30/23   46:2.3M                                   Empire Stock Transf… Inc
10/16/23  Cell MedX Corp.                   10-Q        8/31/23   42:1.9M                                   Empire Stock Transf… Inc
 9/01/23  Cell MedX Corp.                   10-K        5/31/23   73:3.2M                                   Empire Stock Transf… Inc
 6/29/23  Cell MedX Corp.                   10-Q        2/28/23   53:2.5M                                   Empire Stock Transf… Inc
 5/19/23  Cell MedX Corp.                   10-Q       11/30/22   53:2.4M                                   Empire Stock Transf… Inc
 4/19/23  Cell MedX Corp.                   10-Q        8/31/22   51:2.2M                                   Empire Stock Transf… Inc
 4/07/23  Cell MedX Corp.                   10-K        5/31/22   90:3.6M                                   Empire Stock Transf… Inc
 4/11/22  Cell MedX Corp.                   10-Q        2/28/22   56:2.5M                                   Empire Stock Transf… Inc
 1/12/22  Cell MedX Corp.                   10-Q       11/30/21   54:2.4M                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   424B3                  1:365K                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   10-Q        8/31/21   50:2.2M                                   Empire Stock Transf… Inc
10/12/21  Cell MedX Corp.                   424B3                  1:705K                                   Empire Stock Transf… Inc
 8/30/21  Cell MedX Corp.                   10-K        5/31/21   83:3.7M                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   424B3                  1:501K                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   10-Q        2/28/21   56:2.8M                                   Empire Stock Transf… Inc
 1/14/21  Cell MedX Corp.                   10-Q       11/30/20   53:2M                                     Empire Stock Transf… Inc
10/15/20  Cell MedX Corp.                   10-Q        8/31/20   51:1.9M                                   Empire Stock Transf… Inc
 9/15/20  Cell MedX Corp.                   10-K        5/31/20   84:2.9M                                   Empire Stock Transf… Inc
Top
Filing Submission 0001594062-14-000361   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 11:48:03.3am ET